Survey: Coupon clippers most likely are wealthy, educated
MOUNTAIN VIEW, Calif. Wealthy, educated U.S. consumers are more likely to use coupons, according to a new survey conducted by Harris Interactive and Coupons.com.
The telephone survey — conducted from March 5 to 8 — found that among 1,017 adults ages 18 and older, 6-out-of-10 (61%) with a household income of $100,000 or more have redeemed a coupon in the past six months. Additionally, about 4-in-10 adults (39%) in this income bracket have redeemed coupons printed from an online source in the past six months, making them nearly twice as likely to do so as adults with a household income less than $35,000 (21%).
Furthermore, adults with college degrees are almost twice as likely to have used coupons in the past six months as those who didn’t graduate from high school. The survey also showed that this group of grads is more likely to make a purchase specifically to redeem a coupon, visit a product’s Web site to get a coupon and search for coupons online.
“The advent of digital savings tools coupled with a challenging economy has taken couponing mainstream. All sorts of people – including what we call the ‘sophisticated couponer’ – are proudly aboard the couponing bandwagon.” said Steven Boal, CEO of Coupons.com. “We all want the biggest bang for our buck, so the fact that well-heeled, educated and urban shoppers are taking advantage of coupons and searching for them online further illustrates the proliferation of the culture of couponing.”
Dawn Professional names contest winner at industry event
CINCINNATI Procter & Gamble’s Dawn Professional brand has announced the winner of its “Make Your Restaurant Shine” contest at the National Restaurant Association Show in Chicago.
The Dawn Professional line — which provides comprehensive kitchen cleaning solutions to restaurants around the country — awarded Martha Bralkowski, the owner of Jordan’s Bar and Grill in Ridgway, Pa. The award was presented by chef Spike Mendelsohn on the World Culinary Stage, P&G said.
Mendelsohn presented Bralkowski with a $20,000 check for restaurant improvements. She also will receive a one-on-one expert consultation at her restaurant with Mendelsohn later this year. An experienced restaurateur, he will provide expert advice on how to best use the award, share feedback on Jordan’s menu and discuss how to use social media for success. Tips from this session will be featured at www.DawnCelebrations.com.
“Dawn Professional has always been a trusted partner of the restaurant industry, providing products and resources to help restaurants succeed. ‘Make Your Restaurant Shine’ is a way for us to help one deserving restaurant owner — Ms. Bralkowski — in a very personal way,” said Eric Hetrick, director, P&G Professional. “We hope this $20,000 award will help make Jordan’s Bar & Grill an even bigger part of the Ridgway, Penn., community.”
As the winner of the “Make Your Restaurant Shine” contest, Bralkowski also received a paid trip for four adults to the 2010 National Restaurant Association show now underway in Chicago. Contest applications were received online at www.DawnCelebrations.com through April 12.
FDA grants orphan drug designation for Friedreich’s ataxia treatment
WALTHAM, Mass. The Food and Drug Administration has granted special designation to encourage the development of a drug made by Repligen for treating a rare degenerative disease, Repligen said Monday.
Repligen said the FDA’s Office of Orphan Products Development granted orphan drug designation to the drug RG2833, a treatment for Friedreich’s ataxia. The FDA grants orphan drug designation to treatments for rare diseases and grants incentives such as a seven-year market exclusivity period, compared with the usual five years granted to new drugs.
Friedreich’s ataxia is a genetic illness affecting around 15,000 people worldwide that results from a gene defect causing insufficient production of the protein frataxin, leading to degeneration of nerves controlling muscle movements in the arms and legs and nerve tissue in the spinal cord. Symptoms of the disease typically emerge between the ages of 5 and 15 years and lead to severe disability, incapacitation and loss of life in early adulthood.
“We are very pleased to receive orphan drug designation for our Friedreich’s ataxia program,” Repligen CEO Walter Herlihy said. “RG2833 is the first compound that targets activation of the defective gene responsible for Friedreich’s ataxia. If this approach is successful, it has the potential to significantly impact patients’ lives.”